Amlx stock forecast professional AMLX stock forecast

Professional AMLX stock forecast commentary notes tight spreads and consistent institutional coverage, adding credibility to upward revisions in target prices. “Given the failed ADVANCE-2 trial, we remove our sales forecast for Nuplazid in negative symptoms of schizophrenia (NSS),” said analysts at the firm. “Our new $25 PT incorporates value for Nuplazid in Parkinson’s disease psychosis ( PDP ), Daybue with ~$1B peak sales, and potential Nuplazid IP extension into 2038 for PDP .” The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S. Food and Drug Administration approval in 2022 for the treatment of amyotrophic lateral sclerosis (ALS). Amylyx has also filed for regulatory approval of AMX0035 (known as Albrioza) in the European Union and continues to explore its potential utility in other neurodegenerative disorders. In addition to ALS, the Amylyx pipeline includes early-stage programs investigating therapies for Alzheimer’s disease and GM1 gangliosidosis, reflecting the company’s broader commitment to addressing central nervous system pathologies. AMLX stock forecast gained positive attention after management reiterated growth outlook during investor calls, underlining commercial product traction.